Tuesday 23rd February 2016 |
Text too small? |
New Zealand life science and medical research companies will be able to bid for millions of Australian dollars in funding to support new drugs and medical developments after the government signed up to Australia's Medical Research Commercialisation Fund.
New Zealand will pay A$500,000 a year to be part of the fund, the same amount paid by Australian states, Science and Innovation Minister Steven Joyce said in a statement. The fund was set up in 2007 and other investors include Australian Superannuation funds. It is operated by Brandon Capital Partners.
Companies compete for investment and support for the pre-clinical development and commercialisation of discoveries. Early funding can receive up to A$3 million, with the potential for a further A$17 million in investment.
Joyce said the deal was vital in attracting high quality business investment to New Zealand: "Since 2007, the MRCF has supported the development of 24 start-up companies, with some notable successes, such as Spinifex Pharmaceuticals, which sold this year for over US$700 million, and Fibrotech Therapeutics, which netted US$557 million in 2014.”
Ideas and developments are chosen on whether they represent significant breakthroughs, the size and scale of potential markets and the strength of the intellectual property.
BusinessDesk.co.nz
No comments yet
May 29th Morning Report
RAK - Rakon FY2025 Financial Results
WHS - The Warehouse Group appoints Group Chief Executive Officer
General Capital Dividend Reinvestment Plan
FPH - Record full-year revenue result for FPH
Infratil Full Year Results for the year ended 31 March 2025
APL - Annual financial results
ALF - Strong Agri Sector Drives Earnings Growth
Metroglass provides FY25 results (audited)
May 27th Morning Report